(Q72580893)

English

Prazosin, a specific alpha1-noradrenergic receptor antagonist, has no effect on symptoms but increases autonomic arousal in schizophrenic patients

scientific article published on 01 March 1984

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6145176%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

Prazosin, a specific alpha 1-noradrenergic receptor antagonist, has no effect on symptoms but increases autonomic arousal in schizophrenic patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6145176%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

Prazosin, a specific alpha1-noradrenergic receptor antagonist, has no effect on symptoms but increases autonomic arousal in schizophrenic patients (English)

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

1 reference

based on heuristic

inferred from title

adrenergic antagonist

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6145176

14 August 2023

author name string

D. W. Hommer

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6145176

14 August 2023

T. P. Zahn

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6145176

14 August 2023

D. Pickar

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6145176

14 August 2023

D. P. van Kammen

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6145176

14 August 2023

language of work or name

0 references

publication date

1 March 1984

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6145176%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

full work available at URL

https://api.elsevier.com/content/article/PII:0165178184900684?httpAccept=text/xml

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

https://api.elsevier.com/content/article/PII:0165178184900684?httpAccept=text/plain

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

Psychiatry Research

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6145176%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6145176%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6145176%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

193-204

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6145176%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

Methods for reliable longitudinal observation of behavior

3

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

The pharmacology of prazosin, a novel antihypertensive agent

5

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

Increased plasma norepinephrine levels during prazosin therapy for severe congestive heart failure

6

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

α1- and α2-adrenoceptors in rat cerebral cortex: Effects of neonatal treatment with 6-hydroxydopamine

7

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

Noradrenaline distribution insubcortical areas of the human brain

8

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

Norepinephrine in Chronic Paranoid Schizophrenia: Above-Normal Levels in Limbic Forebrain

9

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

Phenothiazine antagonism of the noradrenergic inhibition of cerebellar purkinje neurons

10

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

Skin conductance responsivity during acute episodes of schizophrenia as a predictor of symptomatic improvement

11

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

Noradrenergic Overactivity in Chronic Schizophrenia: Evidence Based on Cerebrospinal Fluid Noradrenaline and Cyclic Nucleotide Concentrations

12

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

Prazosin: the first-dose phenomenon

13

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

Drug therapy. Prazosin

14

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

Binding characteristics of 3H-prazosin to rat brain α-adrenergic receptors

15

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

Effect of propranolol and phenothiazines on electrodermal orienting and habituation in schizophrenia

16

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

Propranolol in schizophrenia. Clinical, metabolic, and pharmacological findings

17

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

Effect of neuroleptics on the disappearance rate of (14C) labelled catecholamines formed from (14C)tyrosine in mouse brain

18

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

Physiologic mechanisms opposing the hemodynamic effects of prazosin

19

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

Methylphenidate, dextroamphetamine, and levamfetamine. Effects on schizophrenic symptoms

20

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

Some clinical and metabolic aspects of propranolol in chronic schizophrenia

21

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

Postmortem studies

22

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

Schizophrenia: elevated cerebrospinal fluid norepinephrine

24

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

Electrophysiologic interactions of antipsychotic drugs with central noradrenergic pathways

25

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

Evidence for a central depressor action of postsynaptic α1-adrenergic receptor antagonists

26

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

Prazosin selectively antagonizes neuronal responses mediated by ?1-adrenoceptors in brain

27

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

3H-prazosin binds specifically to ??1?-Adrenoceptors in rat brain

28

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

Hemodynamic and neuroendocrine responses to acute and chronic alpha-adrenergic blockade with prazosin and phenoxybenzamine.

29

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

Major psychiatric disorders. A four-dimensional model.

31

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

Propranolol in schizophrenia. I. Comparison of propranolol, chlorpromazine and placebo

32

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency

33

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

Neuroleptic drug interactions with norepinephrine alpha receptor binding sites in rat brain

34

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

Propranolol in Schizophrenia: A Double Blind, Placebo Controlled Trial of Propranolol as an Adjunct to Neuroleptic Medication

35

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

II. New evidence for a locus coeruleus-norepinephrine connection with anxiety

36

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

The relative role of dopamine and norepinephrine receptor blockade in the action of antipsychotic drugs: Metoclopramide, thiethylperazine, and molindone as pharmacological tools

37

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

Activation of lateral geniculate neurons by locus coeruleus or dorsal noradrenergic bundle stimulation: selective blockade by the alpha 1-adrenoceptor antagonist prazosin

39

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

Phenothiazine Effects on Psychological and Psychophysiological Dysfunction in Chronic Schizophrenics

42

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

Increase in plasma norepinephrine during prazosin therapy for chronic congestive heart failure

44

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

Modulation of rat brain α- and β-adrenergic receptor populations by lesions of the dorsal noradrenergic bundle

45

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

Alpha-receptor function changes after the first dose of prazosin

46

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

3H-WB 4101 binding in the rat vas deferens. Effects of chronic treatments with desipramine and prazosin

47

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

Prazosin in normal subjects: plasma levels, blood pressure and heart rate

48

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

Propranolol as an adjunct to the treatment of schizophrenia

49

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

DL-propranolol and chlorpromazine following admission for schizophrenia. A controlled comparison

50

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

Autonomic nervous system activity in acute schizophrenia: I. method and comparison with normal controls.

51

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

Autonomic effects of dextroamphetamine in normal men: implications for hyperactivity and schizophrenia

52

1 reference

10.1016/0165-1781(84)90068-4

https://api.crossref.org/works/10.1016/0165-1781(84)90068-4

14 August 2023

Identifiers

10.1016/0165-1781(84)90068-4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6145176%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:6145176%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q72580893&oldid=1953534759"